Understand the benefits and risks of intraperitoneal therapy for advanced ovarian cancer.
Oestreicher
Pamela
P
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods; D007274:Injections, Intraperitoneal / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D009859:Oncology Nursing; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000451:nursing / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D010529:Peritoneal Cavity; D012307:Risk Factors
D000970:Antineoplastic Agents; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin; D008558:Melphalan